APA (7th ed.) Citation

Paracha, N., Reyes, A., Diéras, V., Krop, I., Pivot, X., & Urruticoechea, A. (2020). Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: A systematic review and network meta-analysis. Breast cancer research and treatment, 180(3), 597-609. https://doi.org/10.1007/s10549-020-05577-7

Chicago Style (17th ed.) Citation

Paracha, Noman, Adriana Reyes, Véronique Diéras, Ian Krop, Xavier Pivot, and Ander Urruticoechea. "Evaluating the Clinical Effectiveness and Safety of Various HER2-targeted Regimens After Prior Taxane/trastuzumab in Patients with Previously Treated, Unresectable, or Metastatic HER2-positive Breast Cancer: A Systematic Review and Network Meta-analysis." Breast Cancer Research and Treatment 180, no. 3 (2020): 597-609. https://doi.org/10.1007/s10549-020-05577-7.

MLA (9th ed.) Citation

Paracha, Noman, et al. "Evaluating the Clinical Effectiveness and Safety of Various HER2-targeted Regimens After Prior Taxane/trastuzumab in Patients with Previously Treated, Unresectable, or Metastatic HER2-positive Breast Cancer: A Systematic Review and Network Meta-analysis." Breast Cancer Research and Treatment, vol. 180, no. 3, 2020, pp. 597-609, https://doi.org/10.1007/s10549-020-05577-7.